10th anniversary
ICMRA brings together leaders of medicines regulatory authorities to provide strategic directions for enhanced collaboration, improved communication and approaches to jointly address common public health challenges, such as the COVID-19 pandemic.

ICMRA@10 - safeguarding public health through global strategic leadership and cooperation

### Milestones

**2013**
December: ICMRA is established by 8 regulatory authorities with Health Canada (HC) as chair.

**2014**
August: ICMRA members pledge to support innovative solutions to counter Ebola outbreaks.
November: At the 9th Summit, ICMRA is formally adopted and projects on GMP inspections, generic assessment, capacity building, and mapping of international initiatives are endorsed.

**2015**
November: At the 10th Summit, website and communications strategy are presented.

**2016**
September: Enhancing collaboration to tackle outbreak of Zika virus disease.
October:
- Mapping of international regulatory initiatives published.
- At the 11th Summit, the UK Medicines and Healthcare Products Regulatory Authority (MHRA) is elected as ICMRA chair.

**2017**
October: Agreement on a framework for a project on innovation at the 12th Summit.

**2019**
July:
- Call for a One Health response to antimicrobial resistance across all sectors.
- Stressing the robustness of the assessment and monitoring of biosimilar products.
- Election of the European Medicines Agency (EMA) as new chair.

**2020**
June:
- Explaining the robust scientific and independent assessment of benefits and risks of vaccines carried out by medicines regulators worldwide.
- Stressing the key characteristics of clinical trials that are most likely to generate conclusive evidence to enable the accelerated approval of medicines for COVID-19.

**2021**
January: ICMRA and WHO publish a statement to help healthcare professionals increase trust and confidence of patients in COVID-19 vaccines.
August:
- Setting out recommendations for regulators to address the challenges linked to the use of AI.
- Recommendations to facilitate the use of track and trace systems at global level.
December:
- Reflections on remote approaches to GCP and GMP regulatory oversight during the COVID-19 pandemic.
- Stressing the need for continued focus on COVID-19 therapeutics.

**2022**
June: Inviting industry to participate in pilot programmes focusing on post-approval changes and hybrid inspections.
July:
- EMA is re-elected as ICMRA chair.
- Call for international collaboration to integrate real-world evidence into regulatory decision making.
November: Publication of a report on successful regulatory and non-regulatory interventions to fight AMR.

**2023**
May: A series of workshops on various aspects of COVID-19 vaccines manufacturing, safety and efficacy was held. The 4th workshop establishes key principles for the adaptation of COVID-19 vaccines.
June: ICMRA receives Global Award for Outstanding Contribution to Health from DIA.
July: Reassuring the public on the safety of COVID-19 vaccines.